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1. ABSTRACT 
 
 
The non-syndromic ascending aortic aneurysm is a complex and common 
disease. Little is known on gene expression and its regulation in 
aneurysms.  
The media coat is principally involved in the disease.  
Aim of this study is to identify gene expression differences between 
aneurysmal and normal ascending aortic media coats.  
A total of 41 aneurysmal aortic samples (cases) and 22 aortic samples 
without aneurysm (controls), has been collected from patients undergoing 
aneurysmectomy and heart transplantation, respectively.  
Gene expression analyses on media coats RNA have been conducted by 
whole genome microarrays, which detect a total of 21,329 human genes, 
Real Time PCR, and microRNA microarrays.  
Results from whole genome microarrays performed on 3 cases and a pool 
of 10 controls indicated a total of 17 differentially expressed genes, among 
which Period homolog 2 (PER2), involved in circadian rhythm, was up-
expressed, and Decorin (DCN), involved in remodeling, was down-
expressed. The analysis of 4 pool of 3 cases versus a pool of 15 controls 
confirmed PER2 up-expression. Presently, we validated by Real Time PCR 
PER2 up-expression and DCN down-expression in aneurysms.  
Expression study of a comparison of transcriptomic analysis with 
proteomic data confirmed up-regulation of 6 genes out of 15 investigated, 
including NOTCH1 , involved in vascular development.  
Expression study of selected genes of NF-kB cascade evidenced a pro-
inflammatory status of aneurysmal subjects with bicuspid aortic valve 
compared to the normal and to tricuspid aortic valve aneurysmal subjects.  
Initial microRNA microarray analysis indicates that mir-133, related to 
NO signaling, may be down-regulated in aneurysms.  
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In conclusion, genes mainly involved in inflammation and remodeling 
have been identified with this study. Further expression analyses will 
better indicate pathways involved in thoracic aortic aneurysms 
development. 
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2. INTRODUCTION 
 
 
The aorta is the major artery which arises from the heart. It carries all the 
blood that is pumped out of the heart and distributes it via its many 
branches to all the organs of the body. The aorta is divided into 4 portions: 
1) the ascending aorta , 2) the aortic arch 3) the descending thoracic aorta 
and 4) the abdominal aorta. Aorta's structure is based on three coats, the 
tunicae intima, media and adventitia, each having specific histologic and 
functional features that undergo progressive age-related changes.1,2 Tunica 
intima, the inner layer, consists of an endothelial lining plus longitudinally 
oriented connective tissue elements; tunica media, the middle layer, 
consists of smooth muscle and connective tissue elements arranged in a 
circular or spiral fashion; and tunica adventitia, the outer layer, consists of 
connective tissue elements and some smooth muscle cells arranged 
longitudinally. The vessel is well supplied with nerves (to control the 
media musculature), blood vessels and lymphatics, distributed largely in 
the adventitia. The integrity of the layers is disturbed in some individuals 
by various pathologic processes, the most serious of which increasingly 
stretches an area of the arterial wall, the so called aneurysm, of which 
several kinds are known. Aortic aneurysms contribute to the high overall 
cardiovascular mortality. The incidence of thoracic aortic aneurysms 
(TAA) is estimated at 6 people per 100.000 per year in Western societies,3,4 
and replacement of the ascending aorta accounts for the majority of 
thoracic aortic procedures.5 The mean age at the time of diagnosis ranges 
from 59 to 69 years.1 Men are typically diagnosed at a younger age and 
there is a 2:1 to 4:1 male predominance. Thoracic aneurysms are classified 
according to one or more aortic segments involved (aortic root, ascending 
aorta, arch, or descending aorta). Sixty percent of thoracic aortic 
aneurysms involve the aortic root and/or ascending aorta, 40% involve 
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the descending aorta. The etiology, natural history, and treatment of 
thoracic aneurysms differ for each of these segments. The histopathologic 
abnormality underlying thoracic aortic aneurysms is medial degeneration, 
traditionally termed cystic medial necrosis, which is characterized by the 
triad of loss of smooth muscle cells (SMCs), fragmented and diminished 
number of elastic fibres, and increased accumulation of proteoglycans. 
Medial degeneration leads to weakening of the aortic wall, which in turn 
results in aortic dilatation and aneurysm formation. When such 
aneurysms involve the aortic root, the anatomy is often referred to as 
annuloaortic ectasia. Cystic medial degeneration occurs normally to some 
extent with aging, but the process is accelerated by hypertension. All 
mechanisms that weaken the aortic wall, the aortic lamina media in 
particular, lead to higher wall stress, which can induce aortic dilatation 
and aneurysm formation, eventually resulting in aortic dissection or 
rupture. The occurrence of cystic medial degeneration in young patients is 
classically associated with Marfan syndrome (or with other less-common 
connective-tissue disorders, such as Ehlers-Danlos syndrome). The 
etiopathogenesis of the so called non-syndromic aortic aneurysms, 
affecting the ascending tract in the absence of atherosclerosis, infection or 
Marfan's or Ehlers-Danlos' syndrome, is unkown. The extent of genetic 
heterogeneity is likely to become more evident as more families with 
thoracic aortic aneurysms are studied. It is also possible that this is 
actually a polygenic condition, thus explaining the variable expression 
and penetrance.6 Moreover, many cases of ascending thoracic aortic 
aneurysms are associated with an underlying bicuspid aortic valve.7 
Cystic medial degeneration has been found to be the underlying cause of 
the aortic dilatation associated with a bicuspid aortic valve. In one study, 
75% of people with a bicuspid aortic valve undergoing aortic valve 
replacement surgery had biopsy-proven cystic medial necrosis of the 
ascending aorta, compared with only 14% of those with tricuspid aortic 
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valves undergoing similar surgery. Inadequate production of fibrillin-1 
during embryogenesis may result in both the bicuspid aortic valve and a 
weakened aortic wall. Nevertheless, the genetic alteration in these patients 
with non-syndromic ascending aorta aneurysm is still unknown. The 
anomalous embryonal valvular genesis and the intrinsic weakness of the 
aortic wall could be explained by both semilunar valve and main arteries' 
media coat embryogenetic origin from neural crest. Several assumptions 
have been proposed to elucidate the progressive aortic wall atrophy in 
patients with bicuspid aortic valve: smooth muscle cell apoptosis, fibrillin 
deficiency, increased metalloproteinases secretion. All these conditions 
could explain extracellular matrix destruction and aortic remodelling.8,9 
For explorative purposes the investigation of a great number of genes by 
gene expression approaches could be very efficient in outlining 
transcriptional profiles and molecular pathways involved in the 
etiopathogenesis of the aortic aneurysm. Microarray technique offers the 
possibility of comparing transcriptional profiles between pathological and 
normal tissues. Microarray analysis on genetic specimens from aortic 
media layer is a precious biotechnological tool that may indicate and 
localize the genes and the pathways involved in thoracic aortic aneurysms 
development. Moreover these genes could be analyzed to detect genetic 
variation causing differential gene expression and possibly involved in 
aortic aneurysms. Reportedly, proteomic studies can bridge the gaps 
existing between the results of transcriptional analyses and 
physiopathological and clinical findings. Proteomic approaches could 
explain the functional consequences of genetic and transcriptional 
aberrations. Specific proteins, whose structures, activities, and interactions 
with other proteins are deeply altered, could be identified as triggers of 
physiopathologic mechanisms determining the disease's development.10 A 
better understanding of the processes underlying the disease may also 
arise from the study of microRNA. miRNA are sequence-specific 
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regulators of post-transcriptional gene expression in many eukaryotes. 
They are believed to control the expression of thousand of target mRNAs, 
with each mRNA believed to be targeted by multiple microRNAs.11 
However, the function of most microRNAs is not known. The antisense 
single-stranded microRNAs can bind specific mRNA transcripts through 
sequences that are significantly, though not completely, complementary to 
the target mRNA. This process is also known as post-transcriptional gene 
regulation (PTGS). Some microRNAs can downregulate large numbers of 
target mRNAs,12 and it has been speculated that microRNAs could 
regulate approximately 30% of the human genome.13 MicroRNAs seem to 
be responsible for fine regulation of gene expression, ‘‘tuning’’ the cellular 
phenotype during delicate processes like development and differentiation 
in all organisms, from plants to mammals. A link between microRNAs 
and human diseases, in particular, has been recently shown. Regulation of 
gene expression in the mammalian genome, during development, 
differentiation, and disease, is a complex and multitasked system. To 
make transcripts instead of proteins is energetically ‘‘less expensive’’ for 
cells and could be the reason why regulation at the RNA level is 
‘‘cheaper’’ and more efficient than at the protein level. Penetrance in gene 
expression requires a fine regulation and microRNAs could have a role in 
different phenotypic expressions of the same gene.  
Recent studies have demonstrated that aneurysms associated with 
bicuspid aortic valve (BAV) exhibit striking histological and molecular 
differences compared to aneurysms in patients with trileaflet aortic valve 
(TAV), suggesting that different pathways are responsible for progressive 
aortic dilatation in these two groups.14-17 In a study of Collins et al (2003),18 
detailed findings on 111 BAV and TAV aortic ascending aneurysms were 
described. While the elastic laminae in patients with a BAV remained 
relatively unfragmented, many cases showed numerous areas in which 
SMC were lost and the elastic laminae had become collapsed on each 
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other. SMC loss in patients with a TAV appeared to be associated with 
collagen deposition. However, no overall difference was observed 
between TAV and BAV groups with respect to the grade of SMC loss or 
presence of inflammatory cells. Patients with a TAV did however display 
more frequent intimal changes than patients with a BAV. LeMaire et al. 
(2005) 19 found that histological findings in the BAV group were similar to 
those in control patients; no significant inflammatory infiltrate was seen in 
either group. Aortas from both the BAV group and control group 
displayed evenly distributed SMCs throughout the medial lamellae. 
Aneurysms from TAV patients exhibited severe elastin fragmentation and, 
compared to both BAV aneurysms and control aortas, markedly decreased 
elastin staining. Moreover the same paper shown that at the time of 
aneurysm repair, the pattern of MMP expression and the degree of 
inflammation differ between aneurysms associated with BAVs and those 
with TAVs. Histological differences of ascending AA suggest that 
aneurysms may be the final common manifestation of many different 
disease processes.  
The present study aims to identify genetic factors involved in the non 
syndromic ascending aortic aneurysm onset, analyzing the gene 
expression of the tunicae mediae of aortic fragments. To have a framework 
about which microRNA are implicated in the regulation of the aneurysmal 
pathology at media layer level, we compared, by microRNA microarray, 
BAV group, TAV group and female group respect to the male and female 
groups. Moreover, to investigate if transcriptional differences could 
delineate the different etiopathogenesis for BAV and TAV ascending 
aortic aneurysms we studied the gene expression of twelve actors of NF-
kB signalling. NF-kB is a largely known nuclear factor initially linked by 
researchers to the immune response. A growing appreciation for NF-kB as 
a central mediator of various cardiovascular pathologies has led to the 
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notion that complete inhibition of this pathway will be beneficial in the 
setting of vascular stress and heart disease.20  
The investigation of a great number of genes by the different reported 
gene expression approaches will be performed in this study for 
determining agents and metabolic pathways involved in the 
etiopathogenesis of the ascending aortic aneurysm. 
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3. MATERIALS AND METHODS 
 
3.1. SAMPLES COLLECTION 
 
In collaboration with the Cardiovascular Surgery Section of the University 
of Verona, from September 2005 we collected 41 fragments of aneurysmal 
ascending aorta (cases) and 22 fragments of normal ascending aorta 
(controls, without aneurysm). The cases came from patients presenting 
aneurysm not associates to other syndrome (non-syndromic), undergoing 
aneurysmectomy and the controls came from patients with 
cardiomyopathy, undergoing heart transplantation for a long-lasting past 
medical history of congestive heart failure. The clinical features are given 
for each case and control in the Appendix in Table 1 and in Table 2, 
respectively: sex, age at surgery and aortic valve type. The case group 
included 31 males and 10 females, with a mean age of 64; among cases, 14 
bicuspid, 26 tricuspid, 1 pentacuspid aortic valve were presented. The 
control group included 15 males and 7 females, with a mean age of 57; all 
the controls were with a tricuspid valve. At the time of surgery, after 
tissue resection, ascending aortic specimens were collected and 
immediately immersed into RNAlater, a storage solution which prevents 
the activation of the endogenous RNAses. After 24 hours at 4°C, the 
samples were stored at -20°C until separation of the coats. 
 
 
3.2. SAMPLES PREPARATION  
 
Each fragment of the ascending aorta was divided into the three coats 
(Figure 1) by separation with forceps for dissection and stored in 
separated tubes with RNAlater at -80°C.   
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All the expression analysis have been performed on the media layer, the 
most interesting coat, known as the layer directly involved in the 
pathology. 
 
 
 
Figure 1. Cross section of the aorta with the three separated layers.  
 
 
3.3. RNA PREPARATION 
 
3.3.1. RNA extraction  
The RNA from all the media coats was extracted by the classical TRIzol® 
technique to obtain total RNA. TRIzol is a ready-to-use reagent for the 
isolation of total RNA from cells and tissues. The reagent, a mono-phasic 
solution of phenol and guanidine isothiocyanate, is an improvement to the 
single-step RNA isolation method developed by Chomczynski and 
Sacchi.21  
For detailed steps see Appendix. 
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3.3.2. RNA quantification and quality analysis 
The extracted RNA was quantified by The Thermo Scientific NanoDropTM 
1000 Spectrophotometer (Celbio) (Figure 2) which enables highly accurate 
UV/Vis analyses of 1 ul sample with remarkable reproducibility. Pure 
RNA has a 260/280 Abs ratio of 1.8-2 and a 260/230 Abs ratio of 1.8-2. 
 
 
  
 
Figure 2. A. NanoDrop instrument for the quantification of RNA and B. Agilent 2100 
BioAnalyzer used to valuate the quality of RNA.  
 
The RNA quality was measured by the use of Agilent 2100 Bioanalyzer 
instrument (Figure 3). Very small aliquots of total RNAs were loaded into 
a chip system that contains up to 12 microcapillaries filled with a special 
matrix for the separation of RNA molecules according to their molecular 
weight. The chip is loaded into the Agilent 2100 Bioanalyzer, an electric 
field is applied and a short round of electrophoresis produces a complete 
separation of all the RNA molecules. Capillaries are then scanned by a 
laser source and two type of results are retrieved: 
A) an electropherogram with peaks corresponding to RNA molecules of 
different molecular weight (28S, 18S, 5S) and whose subtended area is 
proportional to the abundance of a specific RNA; 28S area should be twice 
abundant 18S area for the RNA best quality, 
B) an image of a virtual agarose gel separation. 
The output image is shown in Figure 3. 
A.  B.  
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Figure 3. Three Agilent electropherograms indicating a) a quite good, b)  good and c)  
degraded total RNA samples. 
 
 
3.4. MICROARRAY ANALYSIS   
 
For microarray study we used a platform provided by Microcribi of Padua 
consisting of 21,329 70mer oligonucleotides. The procedure to hybridize 
the glass was similar to that cited in our recent paper.22  
Two types of microarray experiments were conducted:  
1- 3 single RNA cases (2 males and 1 female) vs a pool of 10 RNA controls. 
The cases had a tricuspid aortic valve; 
2- 4 pools of 3 RNA cases (all males) each vs a pool of 15 RNA controls. 
Each case pool was composed of both tricuspid and bicuspid aortic valve 
samples.   
Pooling the RNA controls has the aim to minimize the inter-individual 
genetic differences and maximize the typical features of the normal tissue. 
Instead pooling only 3 cases in a sample had the aim to maintain the 
individually features and characterize a lot of sample simultaneously.  
In the same microarray one case (or one pool of cases) and one control 
pool labeled with different dyes, had to be analyzed in a competitive 
b) c) a) 
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hybridization reaction (Figure 4). The dye-swap, consisting in the same 
experiment but with inverted fluorocromes, had been done for each 
microarray, in order to set the biases led by preferential binding of a 
fluorophore and by different steric effects of the dyes chemical moieties. 
It is important to hybridize a balanced number of picomoles of the two 
fluorophores: we decided to use 350 pmol for Cy5 and 400 pmol for Cy3, 
according to different optical characteristics of the two fluorophores. 
 
 
Figure 4. Image of microarray scan in which some subarrays are shown. 
 
 
RNA amplification and labeling  
After quality testing, the RNA had to be amplified and labeled for the 
following hybridization on a microarray.  
To label the target we used the Amino Allyl MessageAmp™ aRNA 
amplification kit (Ambion). The procedure consists of reverse transcription 
with an oligo(dT) primer bearing a T7 promoter using ArrayScript™, a 
reverse transcriptase (RT) engineered to produce higher yields of first 
strand cDNA than wild type enzymes. ArrayScript catalyzes the synthesis 
of virtually full-length cDNA, which is the best way to ensure production 
of reproducible microarray samples. The cDNA then undergoes second 
strand synthesis and clean-up to become a template for in vitro 
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transcription (IVT) with T7 RNA polymerase. To maximize aRNA yield, 
the technology is used to generate hundreds to thousands of antisense 
RNA copies of each mRNA in a sample (In this Protocol the antisense 
amplified RNA is referred to as aRNA; it is also commonly called cRNA). 
The IVT is configured to incorporate the modified nucleotide, 5-(3-
aminoallyl)-UTP (aaUTP) into the aRNA during in vitro transcription. 
aaUTP contains a reactive primary amino group on the C5 position of 
uracil that can be chemically coupled to N-hydroxysuccinimidyl ester-
derivatized reactive dyes (NHS ester dyes), such as Cy™3 and Cy5, in a 
simple, efficient reaction. For each sample we amplified and labeled 1000 
ng of RNA. The schematic procedure is represented in Figure 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Summary of Amino Allyl 
MessageAmp II aRNA amplification 
and labeling procedure  
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The main steps of RNA amplification and labelling are summarized below 
(for experimental details see the Appendix). 
 
Reverse Transcription to synthesize first strand cDNA is primed with 
the T7 Oligo(dT) Primer to synthesize cDNA containing a T7 promoter 
sequence. 
Second Strand cDNA Synthesis converts the single-stranded cDNA into a 
double-stranded DNA (dsDNA) template for transcription. The reaction 
employs DNA Polymerase and RNase H to simultaneously degrade the 
RNA and synthesize second strand cDNA. 
cDNA Purification removes RNA, primers, enzymes, and salts that would 
inhibit in vitro transcription. 
In Vitro Transcription to Synthesize Amino Allyl-Modified aRNA with 
aaUTP generates multiple copies of amino allyl-modified aRNA from the 
double-stranded cDNA templates; this is the amplification step. 
aRNA Purification removes unincorporated NTPs, salts, enzymes, and 
inorganic phosphate to improve the stability of the aRNA and to facilitate 
NHS ester coupling or subsequent enzymatic reactions. 
 
The concentration of the aRNA was been determined by measuring its 
absorbance at 260 nm using NanoDrop spectrophotometer.  
 
aRNA: Dye Coupling Reaction takes place between the amino allyl-
modified UTP residues on the aRNA and amine reactive Cy3 or Cy5 dyes. 
Dye Labeled aRNA Purification removes free dye and exchanges the 
buffer with Nuclease-free Water. 
 
Then, the absorbance of each sample at both 260 nm (A260) and the 
maximum absorbance wavelength for the dye used in the coupling 
reaction (at 550 nm for Cy3 and at 650 nm for Cy5) was measured.   
 
 16
Hybridization of microarray platform 
This step consists of pre-hybridization, hybridization and post-
hybridization phases.  
Pre-hybridization aim to saturate all the sites on the glass area that could 
unspecific bind the target increasing the background noise. 
Hybridization is the crucial step in which the target binds the specific 
oligonucleotide. 
Post-hybridization is a washing step of the slide and removes what is not 
linked. 
For the specific adopted procedure see the Appendix. 
 
3.4.1. Scan of the microarrays 
After hybridization, microarray was scanned with ScanArray Lite 
(PerkinElmer). 
It utilizes proven confocal technology, used to accommodate Cyanine-3 
and Cyanine-5 fluorescent dyes. The scanner only offers 543 nm and 633 
nm excitation wavelengths. 
Signal intensity is balanced across all fluorophores in an array by 
automatically adjusting the laser power or PMT gain to a user defined 
target of pixel intensity for each fluorophore.  
We obtained images from a  5 micrometer resolution producing an 
accurate fluorescence map. The image file format is TIFF.  
 
3.4.2. Statistical analysis of the microarrays 
The fluorescent quantification of the spots was performed by QuantArray 
software overlapping a GAL file and the normalized results are displayed 
in a table in CSV format and a scatter plot. 
The CSV files were opportunely adjusted for their upload in 
ExpressConverter software.  
Express Converter is a file transformation tool that reads microarray data 
files in a variety of file formats and generates TIGR MultiExperiment 
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Viewer file (.mev) as output so that the microarray data can be analyzed 
with MIDAS (Microarray Data Analysis System). 
The data can be compared and the normalization is necessary. This critical 
step can help compensate for variability between slides and fluorescent 
dyes, as well as other systematic sources of error, by appropriately 
adjusting the measured array intensities. Normalization modules include 
locally weighted linear regression (lowess) and total intensity 
normalization. When the normalization and filtering steps are complete, 
MIDAS outputs the data in MEV format. 
So we have highlighted the differential expressed genes by the coefficient 
of variation, in order to filter only the very differentially expressed genes. 
The coefficient of variation describes the magnitude sample values and the 
variation within them; it is assumed that the values are normally 
distributed. We adopted a variation of greater or less of 0,5. 
  
The genes, whose quantification was out of the mean line, and with a log(2)  
>1 or <-1, were considered differentially expressed in the cases respect to 
the controls. 
 
 
3.5. REAL TIME PCR ANALYSIS 
 
Real Time PCR is the continuous collection of fluorescent signal from one 
or more polymerase chain reaction over a range of cycles. Quantitative 
real-time PCR is the conversion of the fluorescent signals from each 
reaction into a numerical value for each sample. We performed two type 
of chemistries used in real-time PCR: SYBR Green I and TaqMan. The first 
was used to relatively quantify the genes revealed in the proteomic study 
and the genes of the NF-kB cascade, whereas the second chemistry was 
used to relatively quantify the genes resulted from the first microarray 
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analysis. The experiments are conducted starting from 3 different newly 
synthesized cDNA to have more statistical power.   
SYBR Green I binds to the minor grove of the double-stranded DNA as the 
double-stranded DNA product is formed. The popularity of SYBR Green I 
assays is due to three factors: low cost for the dye, ease of assay 
development (only a pair of primer is required) and the same detection 
mechanism can be used for every assay. 
TaqMan or hydrolysis probes involves a third, fluorescently labeled 
oligonucleotide, located between the primers, called a probe. The probe 
has been labeled with a reporter on the 5’ end and a quencher on the 3’ 
end. A further advantage of a probe-based assay is the avoidance of 
extraneous signals from primer dimers. When the reporter and quencher 
dyes are in close proximity in solution, the reporter signal is quenched 
while when the Taq polymerases ousts the probe the quencher emits 
fluorescence because no more quenched. 
 
3.5.1. Microarray data confirmation 
We performed Taqman Real Time PCR to confirm the differentially 
expressed genes resulted from the first experiment of microarray. We used 
the same samples of the microarrays. Each couple of primers were tested 
by the standard curve. We used 4 housekeeping genes as reference (ACTB, 
ALDOA, RPS18 and TBP) and valuated them by GeNorm program 
(http://medgen.ugent.be/~jvdesomp/genorm/).23 GeNorm is a popular 
algorithm used to determine the most stable reference (housekeeping) 
genes from a set of tested candidate reference genes in a given sample 
panel. From this, a gene expression normalization factor can be calculated 
for each sample based on the geometric mean of a user-defined number of 
reference genes. 
Then we calculated the normalized relative quantities and then valuated 
them by a unpaired Student t-test corrected of necessary. 
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3.5.2. Merging Transcriptomic and Proteomic data  
The SYBR Green Real Time PCR was performed to investigate expression 
profiles of genes coding for the proteins identified by proteomics analysis 
(prof. Armato, Histology and Embryology Unity, University of Verona) in 
the same group of samples. Two housekeeping genes were used as 
reference (GAPDH and TBP) and a normalization factor was calculated by 
the GeNorm program. The expression profiles of a pool of 7 cases vs a 
pool of 7 controls were obtained using the same statistical analysis 
considered above.  
 
3.5.3. NF-kB cascade genes  
The nuclear factor-kB (NF-kB) signaling pathway plays a key role in 
inflammation as in other ways. The principal involved genes in the NF-kB 
cascade are here valuated by SYBR Green Real-Time PCR: CD14 molecule 
(CD14), heat shock protein 1 (HSP27), nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha (IKBα), conserved 
helix-loop-helix ubiquitous kinase (IKBKA), inhibitor of kappa light 
polypeptide gene enhancer in B-cells, kinase beta (IKBKB), interleukin-1 
receptor-associated kinase 4 (IRAK4), myeloid differentiation primary 
response gene (MD), inhibitor of kappa light polypeptide gene enhancer 
in B-cells, kinase gamma (NEMO), nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 (P50), transferrin receptor (TFR), 
toll-like receptor 4 (TLR4), TNF receptor-associated factor 6 (TRAF6). 
The experiments were performed on three pools of samples:  
- 12 media coat RNAs from male with aneurysm and bicuspid aortic 
valve,  
- 12 media coat RNAs from male with aneurysm and tricuspid aortic 
valve,  
- 12 media coat RNAs from male without aneurysm and with 
tricuspid aortic valve. 
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Each sample was individually analysed for every gene expression and the 
resulting normalized relative quantities have been compared by ANOVA 
test with post test if necessary. 
 
 
3.6. MicroRNA ANALYSIS 
Twenty-five vials containing samples stabilized in RNAlater were shipped 
to MACS Myltenyi Biotech on dry ice to test the differentially expressed 
miRNA by microarray experiments. Each microarray contains 728 human 
miRNA.     
5 pools of 5 RNA each were formed:  
- COM: 5 control RNAs from males, 
- COF: 5 control RNAs from females, 
- ABI: 5 case RNAs from males with bicuspid aortic valve, 
- ATRI: 5 case RNAs from males with tricuspid aortic valve, 
- AF: 5 case RNAs from females with tricuspid valve. 
We tested ABI vs COM, ATRI vs COM, AF vs COF (Table 3). In general, 
control samples were labeled with Cy3 and case samples were labeled 
with Cy5. 
 
Experiment n° Cy3 Cy5 Microarray name 
1 COM ABI A 
2 COM ATRI B 
3 COF AF C 
 
Table 3. Experimental design of the three hybridized microarrays:  
competitive hybridization of COM and ABI (A), COM and ATRI (B) 
 and COF and AF (C).   
 
RNA was isolated using standard RNA extraction protocols (Trizol), and the 
quality were checked via the Agilent 2100 Bioanalyzer platform (Agilent 
Technologies). The fluorescently labeled samples were hybridized overnight to 
topic defined PIQORTM miRXplore Microarrays using the a-HybTM 
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Hybridization Station. Fluorescence signals of the hybridized PIQORTM 
Microarrays were detected using a laser scanner from Agilent (Agilent 
Technologies). Mean signal and mean local background intensities were obtained 
for each spot of the microarray images using the ImaGene software 
(Biodiscovery). Low-quality spots were flagged and excluded from data analysis. 
Unflagged spots were analysed with the PIQORTM Analyzer software. The 
PIQORTM Analyzer calculates all normalized mean Cy5/Cy3 ratios of the four 
replicates per gene. 
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4. RESULTS 
 
The results described below refer to microarray experiments on aortic 
aneurysmal subjects vs normal subjects (4.1), to Real-Time PCR 
experiments to validate selected candidate genes (4.2),  and to microRNA 
study on different subtypes of aneurysmal patients (4.3). 
 
 
4.1. MICROARRAYS 
 
The statistical analysis of microarray experiments on 3 single cases vs a 
pool of 10 RNA controls identified 17 differentially expressed genes, listed 
in Table 4. This relatively small  number of genes is due to the stringent 
analysis performed in order to avoid false positive differentially expressed 
genes.   
 
GB_accession Gene_Symbol Description LOG2  MEDIA 
NM_001920 DCN 017M24_Decorin -1.13 
NM_030819 MGC11335 010L23_Hypothetical protein MGC11335 1.156 
AL080160   046C23_Homo sapiens mRNA 1.054 
NM_006871 RIPK3 044D23_Receptor-interacting serine-threonine kinase 3 1.064 
NM_006475 OSF-2 035B11_Osteoblast specific factor 2 (fasciclin I-like) 1.028 
NM_017805 FLJ20401 041B09_Hypothetical protein FLJ20401 1.025 
AF130075   050K09_Homo sapiens clone FLB9413 PRO2532 mRNA, complete cds 1.034 
AK027302   054I19_Homo sapiens cDNA FLJ14396 fis, clone HEMBA1003291 1.004 
NM_022817 PER2 037B06_Period homolog 2 (Drosophila) 1.033 
AB040892 EPHA8 047N18_EphA8 1.029 
BC008616   033D05_Homo sapiens, clone IMAGE:4178394, mRNA, partial cds 1.139 
AK024599   049L04_Homo sapiens cDNA: FLJ20946 fis, clone ADSE01819 1.167 
NM_020979 APS 030H15_Adaptor protein with pleckstrin homology and src homology 2 domains 1.08 
NM_018433 LOC55818 048A15_Putative zinc finger protein 1.1 
AC004522   041F14_Homo sapiens PAC clone RP4-604G5 from 7q22-q31.1 1.107 
NM_020415 FIZZ3 047F14_Found in inflammatory zone 3 1.064 
NM_001767 CD2 028M01_CD2 antigen (p50), sheep red blood cell receptor 1.16 
 
Table 4. Seventeen differentially expressed genes in single aneurismal RNAs vs a pool of 
10 control RNAs 
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From the statistical analysis of 4 pools of 3 cases vs a pool of 15 RNA 
controls, we identified only 2 up-regulated genes: Period homolog 2 
(PER2) and Coagulation factor III (F3) (Table 5). This result might be due 
to the individual inter-variability that can flatten the expression levels. 
 
 
GB_accession Gene_Symbol Description LOG.MEDIA 
NM_022817 PER2 037B06_Period homolog 2 (Drosophila) 1.069 
NM_001993 F3 015K04_Coagulation factor III (thromboplastin, tissue factor) 1.020 
 
Table 5. Two differentially expressed genes in 4 pool of aneurismal samples vs a control 
pool of 15 RNAs. 
 
Based both on the literature and on our microarray results, Decorin and 
Period homolog 2 genes were firstly selected for further studies by Real 
Time PCR.  
 
 
4.2. REAL TIME PCR 
 
4.2.1. Microarray results’ confirmation 
Validation of the microarray experiments were performed on Period 
homolog 2 and Decorin genes using the same samples considered in the 
first microarray analysis. Real Time PCR results confirmed the up-
regulation of PER2 with a not very significant p-value (p= 0.0539) and the 
down-regulation of DCN with a statistically significant p-value (p= 0.0019) 
(Figure 6). 
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Figure 6. PER2 and DCN gene expression in cases (blue) respect to controls (heavenly). 
 
 
4.2.2. Proteomic-Transcriptomic analysis 
The proteins identified by proteomic study whose genes we analyzed by 
SYBR Green Real Time PCR are: Jagged1 (JAG1), Follistatin-related 
protein 1 (FSTL1), Microfibrillar-associated protein 2 (MFAP2), Vimentin 
(VIM), Testican-2 (SPOCK2), Saposin-A (PSAP), Paxillin (PXN), 
Leiomodin-3 (LMOD3), Cystathionine gamma-lyase (CTH), Tumor 
necrosis factor receptor superfamily member 27 (EDA2R), Epiphycan 
(EPYC), Carbonic anhydrase-related protein (CA8), Glial fibrillary acidic 
protein (GFAP), and Notch homolog 1, translocation-associated 
(NOTCH1). 
Moreover, Real Time PCR analysis was performed in genes coding for 
proteins whose levels have been found differentially expressed by the 
proteomic analysis. Seven aneurismal samples have been compared to 
seven control samples in this proteomic-genetic study. The results of both 
proteomic and semiquantitative gene expression analysis are reported in 
Table 6. Figure 7 shows transcriptomic results.  
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UniProt Protein name Gene name 
Proteomic 
results 
Real Time 
PCR 
P78504 Jagged1 JAG1 ↑ - 
Q12841  Follistatin-related protein 1 FSTL1 ↓ - 
P55001 Microfibrillar-associated protein 2 MFAP2 ↑ ↑ 
P08670 Vimentin VIM ↓ ↑ 
Q92563  Testican-2 SPOCK2 ↑ ↑ 
P07602 Saposin-A PSAP ↓ - 
P49023 Paxillin PXN ↑ - 
Q0VAK6 Leiomodin-3 LMOD3 ↑ - 
P32929 Cystathionine gamma-lyase CTH ↑ ↑ 
Q9HAV5 Tumor necrosis factor receptor superfamily member 27 EDA2R ↓ - 
Q99645  Epiphycan EPYC ↑ - 
P35219 Carbonic anhydrase-related protein CA8 ↓ - 
Q9H382 Fibronectin 1 FN1 ↑ ↑ 
P14136 Glial fibrillary acidic protein GFAP ↑ ↑ 
P46531 Notch homolog 1,translocation-associated NOTCH1 ↑ ↑ 
 
Table 6. Differentially expression levels of proteins and their coding genes in seven cases 
compared to seven controls. ↑= up-regulation, ↓= down-regulation, - = no differential  
expression. 
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Figure 7. Gene expression levels selected on the basis of proteomic analysis in cases 
(blue) respect to controls (heavenly). p-value is given below each gene. 
 
JAG1, LMOD3, CA8 genes were not differentially expressed in cases. The 
data confirm the up-regulation at transcriptional level of MFAP, VIM, 
SPOCK2, CTH, FN1, GFAP and NOTCH1 genes (p-value<0,05). For the 
other 5 investigated genes, up-regulation was not statistically significant.   
 
4.2.3. NF-kB pathway analysis 
The results of Real Time PCR analysis on twelve selected genes involved 
in the NF-kB pathway from BAV and TAV cases and from controls are 
given as normalized relative quantity means in Figure 8. The analysis was 
conducted on 12 bicuspid aneurysmal samples, 12 control samples and 12 
tricuspid aneurysmal samples.   
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Figure 8. Gene expression profiles of 12 genes involved in NF-kB cascade. The expression 
levels are reported in BAV (turquoise), Controls CTRL (heavenly), and in TAV (blue) 
samples for each gene. P-values are shown below the genes. 
 
The general profile of the data indicate that in bicuspid aneurysmal group, 
the NF-kB involved genes are up-regulated respect to the control group 
and the tricuspid aneurysmal group resulted down-regulated. Only 
IRAK4 resulted down-regulated and NEMO was not differentially 
expressed in bicuspid aneurysmal group. Instead, only HSP27 resulted 
up-regulated and IKBKA was not differentially expressed in tricuspid 
aneurysmal group.  
After correction for multiple testing, the threshold of statistical 
significance was set at P<0.0042 and significant p-value was obtained in all 
the genes except CD14, HSP27, and IRAK4.   
 
4.3. miRNA results 
 
microRNA differential expression profile has been analysed in the 
following three groups: bicuspid aneurysmal males (group A), tricuspid 
aneurysmal males (group B), and tricuspid aneurysmal females (group C).  
The miRNAs found down-regulated both in tricuspid aortic valve males 
and in tricuspid valve females were: mir486-5p, mir133a, mir133b, mir940, 
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mir125a-3p. The common target genes for all these miRNAs are KCNA1, 
KLK2, CD47, ARF3, SLC1A2, OCRL, ZNF37A, and CASC4.  
The miRNAs found up-regulated both in tricuspid valve males and in 
tricuspid valve females were: mir15a, mir21, mir25, mir146b-5p, mir29b, 
mir142-5p, mir422a, mir21*, and mir138-1*. GPR180 is the common target 
gene for all these miRNAs.   
The up-regulated miRNAs in all the three groups were: mir487b and 
mir128. Several genes are regulated by these two miRNAs: SMAP1, 
MAP2K4, ZNF831, NTNG1, YWHAB, IDS, CD47, LAPTM-4B, RPS6KB1, 
CEP350, NRP1, PCF11, USP25, KLHL3, LOC6-43837, NAV1, UNC13C, 
NAB1, BTB11, SMAD2, RPL10, RCOR1, MUC3B, RNF182, and ZNF664. 
Only miRNAs differentially expressed more than 1,5 fold and for at least 
in two categories have been considered as putative candidate miRNAs 
and are highlighted by green and red color in Table 7. Green color 
indicates a <0.66-fold downregulation, corresponding to a fold change <–
1.5 of a certain miRNA in comparison to the control sample. Red color 
indicates a more than 1.5-fold induction of the respective miRNA in 
comparison to the control.  
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miRNA name A B C 
MIR-486-5P: HSA-MIR-486-5P; MMU-MIR-486 0.717679 0.573901 0.569565 
MIR-133A: HSA-MIR-133A; MMU-MIR-133A; RNO-MIR-133A 0.832375 0.562239 0.481803 
MIR-133B: HSA-MIR-133B; MMU-MIR-133B; RNO-MIR-133B 0.850565 0.562562 0.5002 
MIR-940: HSA-MIR-940   0.478094 0.447289 
MIR-125A-3P: HSA-MIR-125A-3P; MMU-MIR-125A-3P; 
RNO-MIR-125A-3P 0.704419 0.571557 0.473368 
MIR-15A: HSA-MIR-15A; MMU-MIR-15A; RNO-MIR-15A 1.094296 3.087589 1.853837 
MIR-21: HSA-MIR-21; MMU-MIR-21; RNO-MIR-21 1.131506 4.693228 2.710697 
MIR-25: HSA-MIR-25; MMU-MIR-25; RNO-MIR-25   2.798133 1.662063 
MIR-146B-5P: HSA-MIR-146B-5P; MMU-MIR-146B; RNO-
MIR-146B   3.996174 2.749153 
MIR-29B: HSA-MIR-29B; MMU-MIR-29B; RNO-MIR-29B 0.957466 1.741177 1.509631 
MIR-142-5P: HSA-MIR-142-5P; MMU-MIR-142-5P; RNO-
MIR-142-5P   4.419103 2.69759 
MIR-422A: HSA-MIR-422A   2.346378 1.55708 
MIR-21*: HSA-MIR-21*   4.208886 2.461323 
MIR-138-1*: HSA-MIR-138-1* 1.241529 3.487538 1.818019 
MIR-150*: HSA-MIR-150* 2.337072 1.520459 1.394708 
MIR-487B: HSA-MIR-487B; MMU-MIR-487B; RNO-MIR-487B 2.045596 1.670535 1.704477 
MIR-128: HSA-MIR-128; MMU-MIR-128; RNO-MIR-128 1.824481 4.799245 2.130095 
 
Table 7. miRNA differential expression as log2 in bicuspid aneurysmal males (A), 
tricuspid aneurysmal males (B), and tricuspid aneurysmal females. Down- regulated and 
up-regulated miRNA are indicated in green and red, respectively. microRNAs not 
highlighted represent those not differentially expressed or those for which there was not 
microarray data 
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5. DISCUSSION 
 
Sixty percent of thoracic aortic aneurysms involve the ascending aorta.24 
Research into the pathogenesis of ascending aortic aneurysms is difficult, 
because this disease is caused by multiple factors, such as hemodynamic, 
metabolism, inflammation and genetic influences. In addition to activation 
of proteolysis and inflammation, apoptosis of smooth muscle cells and 
oxidative stress have been suggested by several clinical-pathological 
studies, and these factors, together with many others, seem to be 
intricately interwoven to produce aneurysms. Another difficulty is that 
suitable animal models are not available for the study of aortic aneurysms. 
In this respect, the use of a microarray technique with human samples, 
which can evaluate thousands of genes simultaneously, is of great value 
and several reports regarding this method in aortic aneurysms have been 
recently published.25-27  
The present study is the first one on differential gene expression analysis 
in media from aorta specimens with and without aneurysm; the media is 
the most important coat involved in the ascending aortic aneurysms. 
Aortic wall thinning and medial smooth muscle cells (SMC) loss is a 
common finding in aortic wall specimens.28,29  
In microarray study we took into consideration only patients with 
tricuspid aortic valve and not many genes were been identified 
differentially expressed. The results revealed genes involved in 
morphological and cytoskeletal changes that may lead to the remodeling 
of aortic wall, while minimal implication of inflammatory pathways seems 
to be predicted. In particular, until now, we have confirmed the data for 
two of these.  
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Decorin (DCN) 
One of these is Decorin, small cellular or pericellular matrix proteoglycan 
that is closely related in structure to biglycan protein. Proteoglycans serve 
several functions in the artery wall, including regulation of cell adhesion, 
migration, and proliferation. The major proteoglycan in the arterial ECM 
synthesized by arterial smooth muscle cells (ASMC) is the large 
chondroitin sulphate proteoglycan versican, also known as PG-M that can 
form large aggregates. These large aggregates contribute to tissue 
mechanical properties, providing a hydrated sponge-like matrix that 
resists or cushions against deformation. Arteries also contain smaller 
proteoglycans that contain dermatan sulphate glycosaminoglycans such as 
decorin and biglycan, which interact with other ECM proteins and with 
macromolecules that enter the vascular wall such as low density 
lipoproteins. Not all vascular proteoglycans would be regulated similarly. 
It has been shown that decorin is specifically decreased by strain. Because 
decorin binds to collagen30 and regulates collagen cross-linking,31 the 
decrease in decorin could promote disorganization of collagen and a 
loosening of ECM. Decorin can link LDL and collagen type I in vitro. It is a 
component of the blood vessel proteoglycans (PG) synthesized by 
vascular cells, important for collagen assembly and stability. A decrease of 
decorin in ascending aortic aneurysms vs normal aorta may be the cause 
for disordered collagen deposition in the aneurysmal wall.32 
 
Period homolog 2 (PER2) 
Another curious gene resulted from both microarray experiments is 
Period homolog 2 (PER2), one of the genes involved in the circadian clock 
rhythm. Daily behavioural and physiological rhythms in mammals are 
driven by the circadian pacemaker in the suprachiasmatic nucleus (SNC) 
of the hypothalamus,33 which orchestrates a hierarchy of molecular clocks 
in tissues throughout the organism, including heart and vasculature.34 
Peripheral oscillators are synchronized by various neurohumoral stimuli 
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and food or metabolic cues by several peripheral clocks. One potential 
function of a peripheral clock is to regenerate a weak or dampened SCN 
signal, thus amplifying the oscillation of the signal in each tissue. Another 
is to coordinate locally clock controlled gene expression in each tissue 
generating an amplified and synchronized rhythm in response to 
asynchronous blood borne signals.35 The morning pattern of increased 
frequency of AAA rupture or aortic dissection resembles that of many 
other acute cardiovascular diseases, such as acute myocardial infarction,36 
and sudden death.37 This suggests that common underlying 
pathophysiologic mechanisms may be responsible for triggering these 
cardiovascular events. The onset of cardiovascular events is triggered by 
several pathophysiologic events, in particular, an increase in blood 
pressure, heart rate, basal vascular tone, vasoconstrictive hormones, which 
exhibit prominent circadian rhythms with phases that are positively 
correlated with the timing of excess in cardiovascular events.38 There are 
close relationships between blood pressure rhythms and temporal 
patterns of cardiovascular events.39 Blood pressure reaches peak values in 
the morning, although a secondary peak is usually present in the late 
afternoon or early evening.40  
It is presumed that such forces act on the aortic wall, which is inherently 
weakened by genetic and acquired disorders, triggering acute aneurysm 
rupture or dissection in the early morning hours (Fig 9).41 As blood 
pressure undergoes circadian rhythms during the day, it is possible that 
pressure acts as a synchronizer for peripheral clocks. Thus, chronic 
pressure overload occurring locally on the heart would be expected to 
modulate the clock.  
Aortic constriction increases the local pressure on the heart, which 
subsequently maintains cardiac output through the development of 
hypertrophy. Mechanical stress on cardiomyocytes, caused by increased 
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blood pressure, for example, induces a cascade of intracellular signaling 
events resulting in alterations in gene expression. 
We found PER2 over-expressed in our microarray study and this could 
maintain active the cycle resulting in an overloaded blood pressure on the 
wall. 
 
 
 
 
Figure 9. Concurrent pathophysiologic mechanisms underlying circadian variation of 
aortic rupture or dissection. BP, Blood pressure; HR, heart rate; tPA, tissue plasminogen 
activator; PAI-1, plasminogen activator inhibitor-1.  
 
 
 
Transcriptomics vs Proteomics 
Despite the obvious attractions of parallel profiling of transcripts and 
proteins on a global ‘omic’ scale, there are practical and biological 
differences involved in their application. Transcriptomics is now a robust, 
high-throughput, cost-effective technology capable of simultaneously 
quantifying tens of thousands of defined mRNA species in a miniaturized, 
automated format. Conversely, proteomic analysis is currently much more 
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limited in breadth and depth of coverage owing to variations in protein 
abundance, hydrophobicity, stability, size and charge. Nevertheless, 
transcriptomic and proteomic data can be compared and contrasted 
provided the studies are carefully designed and interpreted. Differential 
splicing, post-translational modifications and data integration are among 
some of the future challenges to tackle. Early studies suggested that 
mRNA levels cannot be consistently relied upon to predict protein 
abundance.42,43 On the biological front, differences can result from RNA 
splicing that is not detectable by the classical microarray platform in use, 
differential RNA and protein turnover, post-translational modifications, 
allosteric protein interactions and proteolytic processing events. On the 
experimental front, challenges in experimental design and data 
interpretation, as well as technological limitations, contribute to some of 
the differences observed.44  
The differential expression levels (up or down) of the genes resulted from 
the parallel proteomic study have been just in part confirmed with relative 
quantification of transcripts by Real Time PCR. In some cases we were not 
able to find the some expression profile for the protein and the 
corresponding transcripted gene. For example, for JAG1, PXN, LMOD3, 
and EPYC proteins were up-expressed, instead the transcripts not resulted 
differentially expressed. FSTL1, PSAP, EDA2R, and CA8 proteins were 
down-expressed and their genes were not differentially expressed. In the 
case of VIM, the proteomic (down) and transcriptional (up) profiles were 
opposite. 
Some proteins resulted interesting for the involvement in ascending aortic 
aneurysms. 
 
 
NOTCH1 and JAG1 
Proteomic study revealed an over-expression of JAG1 protein. This result 
was not confirmed by Real Time PCR of the corresponding gene 
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expression, so we decided to evaluate the target receptor of JAG1, 
NOTCH1. Interestingly, NOTCH1 resulted up-regulated by both 
proteomic and transcriptomic analysis.  
Notch signaling is an extremely conserved and widely used mechanism 
regulating cell fate in metazoans. Interaction of Notch receptors (Notch) 
with their ligands (Delta-like or Jagged) leads to cleavage of the Notch 
intracellular domain (NICD) that migrates into the nucleus. In the nucleus, 
NICD associates with a transcription factor, RBP-Jk. The NICD-RBP-Jk 
complex, in turn, up-regulates expression of primary target genes of 
Notch signaling, such as Jagged1. Recent evidence has demonstrated that 
the Notch pathway is involved in multiple aspects of vascular 
development, including proliferation, migration, smooth muscle 
differentiation, angiogenic processes, and arterial-venous differentiation.45 
Recent findings implicate Notch as playing a critical and non-redundant 
role in vascular development and maintenance.46 Lindner et al. found that 
both smooth muscle cells and endothelial cells of the vasculature greatly 
increase the expression of these genes in vivo after injury, and that levels 
of Notch receptor expression may be related to endothelial cell/smooth 
muscle cell interaction. In general, although Notch1 and Jagged1 and 2 
were found expressed at low levels in normal endothelium, there was no 
expression of Notch2 through 4. All genes were induced after injury, and 
it is interesting to note that the expression of Notch receptors seemed to be 
higher in smooth muscle cells in regions of contact with endothelial cells.47 
In our study we found an over expression of both Notch1 and Jagged1 
proteins and NOTCH1 gene as an answer to damage vessel. It remains 
unknown which is the signal that acts like an injury to the aortic wall and 
if the increased expression of NOTCH1 and JAG1 is a cause or an effect of 
the signalling.  
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Cystathionine gamma-lyase (CTH) 
Cystathionine gamma-lyase (CTH) is a key enzyme in the trans-
sulfuration pathway, which uses L-cysteine to produce hydrogen sulfide 
(H2S). The CTH/H2S system has been shown to play an important role in 
regulating cellular functions in different systems. G. Yang et al.48 found 
over-expressed CTH in human aorta smooth muscle cells (HASMCs) 
using a recombinant defective adenovirus containing CTH gene (Ad-
CTH). Infection of HASMCs with Ad-CTH resulted in a significant 
increase in the expression of CTH protein and H2S production. Ad-CTH 
transfection inhibited cell growth and stimulated apoptosis. CTH is the 
dominant H2S-generating enzyme in cardiovascular system.49,50 
Consistent with these evidences we found CTH over-expressed at protein 
and in transcription levels. Abnormal metabolism and functions of 
endogenous H2S, producted by CTH, may impact on vascular contractile 
status and structural remodeling of blood vessel walls under different 
pathophysiological conditions.51 
 
Fibronectin1 (FN1) 
We found Fibronectin1 (FN1) up-regulated in both transcriptional and 
proteomic approaches. As reported, Fibronectin is an extracellular matrix 
protein found only in vertebrate organisms containing endothelium-lined 
vasculature and is required for cardiovascular development in fish and 
mice. Fibronectin and its splice variants containing EIIIA and EIIIB 
domains are highly up-regulated around newly developing vasculature 
during embryogenesis and in pathological conditions including 
atherosclerosis, cardiac hypertrophy, and tumorigenesis. Recent genetic 
studies in fish, frogs and mice have suggested that FN1 functions in 
maintaining or establishing cell polarity and highlighted the role of FN1 
and its splice variants in development of vascular smooth muscle cells.52 
All these differentially expressed genes are involved in morphological and 
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cytoskeletal changes that may lead to the remodeling and can alter the 
structural integrity of the aortic wall.  
 
NF-kB 
The NF-kB pathway genes resulted up-regulated in BAVs and down-
regulated in TAVs respect to controls. The objective of this part of 
investigation was to compare the patterns of gene expression in aortas 
between TAV and BAV patients with and the aim to identify markers for 
ascending aortic aneurysms (AscAAs). Although most AscAAs occur in 
the presence of a trileaflet aortic valve (TAV), a bicuspid aortic valve 
(BAV) is a common congenital anomaly associated with an increased risk 
for an AscAA and dissection independent of functional valve pathology 
but secondary to inherent structural abnormality of the aorta.53 MJ Collins 
et al.18 found that ascending aortic aneurysms are rarely associated with 
inflammatory infiltrates in the aortic media of TAV patients. Aortic wall 
damage in trileaflet aortas develops in several phases and it is both longer 
standing and more severe than it is in bicuspid aortas (Figure 10). As far as 
the bicuspid group is concerned, studies indicate that all congenitally 
bicuspid aortic valves are already morphologically stenotic at birth. Even 
in the absence of clinical symptoms and of significant pressure gradient, 
bicuspid valves create turbulence in the ascending aorta which is more 
than enough to cause aortic wall changes and dilatation.54 
 
 38
 
Figure 10. Mechanism of the development of changes in the microstructure  
of the ascending aorta. 
 
 
Our findings suggest that the inflammatory response is more activated in 
BAV ascending aortic aneurysm than in the control group. CD14, HSP27, 
IKBα, IKBKA, IKBKB, IRAK4, MD, NEMO, P50, TFR, TLR4, TRAF6 genes 
were up-regulated. Only HSP27 had a inverse profile. In TAV ascending 
aortic aneurysm group the inflammatory signal was down-regulated 
respect to the control group and this is consistent with the study of Franz-
Xaver Schmid et al.16 that examined the degree of smooth muscle cell 
rarefication, leukocyte infiltration, and expression of cell death-initiating 
proteins at the tissue level in ascending aortic aneurysms of patients with 
bicuspid and tricuspid aortic valve. The study confirmed that patients 
with congenitally bicuspid aortic valve have more severe inflammatory as 
well as degenerative changes in the medial layer than patients with 
tricuspid aortic valve disease. Although there was no difference in 
infiltrating leukocyte subsets, patients with a bicuspid aortic valve had 
fewer numbers of SMCs depicted by a significantly increased apoptotic 
index for all medial cells, but especially for SMCs. Pathology studies have 
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clearly demonstrated an association between bicuspid aortic valve and 
aortic medial abnormalities.55 
 
microRNA 
Little can be said about microRNA study. We found mir133A and mir133B 
down-regulated in male and female TAV group. mir133 was found as a 
key regulator of cardiac hypertrophy and microarray and northern blot 
analyses revealed that mir-133 is expressed only in the heart and skeletal 
muscle of human embryos and adults, whereas it is virtually absent from 
other tissues.56 One of the target genes of miRNA-133 is CD47. CD47, 
originally named integrin-associated protein, is a receptor for 
thrombospondin-1. Recent discovery that thrombospondin-1 acts via 
CD47 to inhibit nitric oxide signaling throughout the vascular system has 
given new importance and perhaps a unifying mechanism of action to 
these enigmatic proteins.57 Several miRNAs are highly expressed in the 
hearth and recent data suggest their implication in the control of 
cardiovascular development and disease as well, raising hope for a new 
therapy paradign of cardiovascular diseases.58 In vascular cells, miRNAs 
have been linked to vasculoproliferative conditions such as angiogenesis 
and neointimal lesion formation.  
 
Possibilities for diagnostic, prognostic, and therapeutic use of individual 
miRNAs or miRNA clusters in cardiovascular diseases will have to be 
further explored.   
All these studies revealed genes largely involved in the remodeling, 
structural integrity and maintenance of the aortic wall.     
Future investigations by microarrays will be conducted in order to 
identify pathways implicated in AscAA, as indicated in our recent paper 
on atherosclerosis gene expression,22 in which gene networks were 
identified.  
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6. CONCLUSION 
 
 
The present study considered the non-syndromic ascending aortic 
aneurysm by different gene expression analysis techniques. Microarray 
and Real Time PCR studies had revealed genes involved in the structural 
integrity of aortic vessel, in remodeling and in maintenance of the correct 
blood flow. A component of inflammation had been found in aneurysmal 
subjects with bicuspid aortic valve respect to normal and to aneurysmal  
subjects with tricuspid aortic valve, underlining that the bicuspid valve 
predisposes to an inflammatory process in the media coat. We identified 
microRNAs implicated in the disease at media coat level, but is still too 
early to say their effective involvement in the development of the disease. 
This is a study in progress and further analysis will be done. First, the 
completion of the microarray analysis to all media coat samples could give 
more informative results about the genes involved in the pathogenesis of 
the thoracic aortic aneurysm. This will confer a strong statistical power to 
the study and highlight signaling pathway. Then, gene expression analysis 
on the intima and media coats could give a more precise localization of the 
pathology’s course. 
The integration of the different findings of this research will lead to a 
deeper understanding of the etiopathogenesis of ascending aortic 
aneurysm and will be useful in identifying individuals at risk of disease 
who should be directed towards early detection programs. 
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7. APPENDIX 
 
7.1. SAMPLE COLLECTION 
 
CONTROLS sex Age at surgery valve type 
1C M 46 tricuspid 
2C M 48 tricuspid 
3C M 50 tricuspid 
4C F 68 tricuspid 
5C F 55 tricuspid 
6C M 56 tricuspid 
7C F 67 tricuspid 
8C M 63 tricuspid 
9C M 53 tricuspid 
10C M 63 tricuspid 
11C M 57 tricuspid 
12C M 61 tricuspid 
13C M 51 tricuspid 
14C M 61 tricuspid 
15C M 58 tricuspid 
16C M 68 tricuspid 
17C M 54 tricuspid 
18C M 67 tricuspid 
19C F 51 tricuspid 
20C F 56 tricuspid 
21C F 40 tricuspid 
22C F 64 tricuspid 
 
Table 1. Clinical features of the control subjects. 
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CASES sex Age  at surgery valve type 
1A M 65 bicuspid 
2A M 65 tricuspid 
3A F 64 tricuspid 
4A M 69 tricuspid 
5A F 71 tricuspid 
6A F 72 tricuspid 
7A M 60 tricuspid 
8A M 43 bicuspid 
9A F 36 tricuspid 
10A F 75 tricuspid 
11A F 74 tricuspid 
12A F 65 bicuspid 
13A M 63 tricuspid 
14A M 66 tricuspid 
15A M 65 bicuspid 
16A M 60 tricuspid 
17A M 62 bicuspid 
18A M 67 bicuspid 
19A M 52 bicuspid 
20A M 44 bicuspid 
21A M 77 bicuspid 
22A M 63 tricuspid 
23A M 38 tricuspid 
24A M 63 tricuspid 
25A M 71 tricuspid 
26A M 53 bicuspid 
27A M 74 tricuspid 
28A M 60 tricuspid 
29A F 75 tricuspid 
30A M 74 tricuspid 
31A F 78 tricuspid 
32A M 63 tricuspid 
33A M 61 bicuspid 
34A M 77 bicuspid 
35A M 62 bicuspid 
36A M 70 tricuspid 
37A M 68 bicuspid 
38A F 74 tricuspid 
39A M 66 tricuspid 
40A M 60 tricuspid 
41A M 44 pentacuspid 
 
Table 2. Clinical features of the case subjects. 
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7.2. RNA EXTRACTION 
 
The RNA from all the media coats was extracted by the classical TRIzol® 
technique with the following steps: 
- 5 minutes homogenization of TRIzol immersed sample by 
UltraTurrax 8.0; 
- remove insoluble material from the homogenate by centrifugation 
at 12,000 × g for 10 minutes at 2 to 8°C; 
-  incubate the homogenized samples for 5 minutes at room 
temperature (RT); 
- add 0.2 ml of chloroform per 1 ml of TRIZOL® Reagent; 
- shake tubes vigorously by hand for 15 seconds; 
- incubate them at RT for 2 to 3 minutes; 
- centrifuge the samples at 12,000 × g for 15 minutes at 4°C; 
- transfer the aqueous phase to a fresh tube; 
- add 0.5 ml of isopropyl alcohol per 1 ml of TRIZOL® Reagent; 
- incubate samples at RT for 10 minutes;  
- centrifuge at 12,000 × g for 10 minutes at 4°C (the RNA precipitate, 
often invisible before centrifugation, forms a gel-like pellet on the 
side and bottom of the tube.); 
- remove the supernatant;  
- wash the RNA pellet once with 75% ethanol, adding at least 1 ml of 
75% ethanol per 1 ml of TRIZOL® Reagent:  
- centrifuge at 7,500 × g for 5 minutes at 4°C; 
- resuspend the RNA with 15 µl nuclease-free water.  
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7.3. MICROARRAY EXPERIMENTS  
 
7.3.1. RNA AMPLIFICATION  
 
7.3.1.1. Reverse Transcription to synthesize first strand cDNA 
 
The reverse transcription is primed with the T7 Oligo(dT) Primer to 
synthesize cDNA containing a T7 promoter sequence. 
a. Add to 1000 ng of total RNA 1 μL of T7 Oligo(dT) Primer. 
b. Add Nuclease-free Water to a final volume of 12 μL, vortex briefly to 
mix, then centrifuge to collect the mixture at the bottom of the tube.  
c. Incubate 10 min at 70°C in a thermal cycler. 
d. Centrifuge samples briefly (~5 sec) to collect them at the bottom of the 
tube. Place the mixtures on ice. 
e. At room temp, prepare Reverse Transcription Master Mix in a nuclease-
free tube composed (for a single 20 μL reaction) by: 
2 μL 10X First Strand Buffer 
4 μL dNTP Mix 
1 μL RNase Inhibitor 
1 μL ArrayScript 
f. Mix well by gently vortexing. Centrifuge briefly (~5 sec) to collect the 
Reverse Transcription Master Mix at the bottom of the tube and place on 
ice. 
g. Transfer 8 μL of Reverse Transcription Master Mix to each RNA sample. 
Mix thoroughly by pipetting up and down 2–3 times, then flicking the 
tube 3–4 times, and centrifuge briefly to collect the reaction in the bottom 
of the tube. 
h. Incubate the samples in a 42°C incubator (we used a water bath) for 2 
hr. 
i. After the incubation, centrifuge briefly (~5 sec) to collect the reaction at 
the bottom of the tube. 
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7.3.1.2. Second Strand cDNA Synthesis 
 
In this step the single-stranded cDNA is converted into a double-stranded 
DNA (dsDNA) template for transcription. The reaction employs DNA 
Polymerase and RNase H to simultaneously degrade the RNA and 
synthesize second strand cDNA. 
a. On ice, prepare a Second Strand Master Mix in a nuclease-free tube (for 
a single 100 μL reaction) in the order listed following: 
63 μL Nuclease-free Water 
10 μL 10X Second Strand Buffer 
4 μL dNTP Mix 
2 μL DNA Polymerase 
1 μL RNase H 
b. Mix well by gently vortexing. Centrifuge briefly (~5 sec) to collect the 
Second Strand Master Mix at the bottom of the tube and place on ice. 
c. Transfer 80 μL of Second Strand Master Mix to each sample. Mix 
thoroughly by pipetting up and down 2–3 times, then flicking the tube 3–4 
times, and centrifuge briefly to collect the reaction in the bottom of the 
tube. 
d. Incubate the tubes for 2 hr in a 16°C water bath.  
e. After the 2 hr incubation at 16°C, place the reactions on ice and proceed. 
 
7.3.1.3. cDNA Purification 
 
The purification permits to remove RNA, primers, enzymes, and salts that 
would inhibit in vitro transcription. 
a. Add 250 μL of cDNA Binding Buffer to each sample, and mix 
thoroughly by pipetting up and down 2–3 times, then flicking the tube 3–4 
times. Follow up with a quick spin to collect the reaction in the bottom of 
the tube. Proceed quickly to the next step. 
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b. Pipet the cDNA sample\cDNA Binding Buffer (from step 1) onto the 
center of the cDNA Filter Cartridge. 
c. Centrifuge for ~1 min at 10,000 x g, or until the mixture is through the 
filter. 
d. Discard the flow-through and replace the cDNA Filter Cartridge in the 
wash tube. 
e. Apply 500 μL Wash Buffer to each cDNA Filter Cartridge. 
f. Centrifuge for ~1 min at 10,000 X g, or until all the Wash Buffer is 
through the filter. 
g. Discard the flow-through and spin the cDNA Filter Cartridge for an 
additional minute to remove trace amounts of Wash Buffer. 
h. Transfer cDNA Filter Cartridge to a cDNA Elution Tube. 
i. Apply 9 μL of Nuclease-free Water (preheated to 50–55°C) to the center 
of the filter in the cDNA Filter Cartridge. 
j. Leave at room temperature for 2 min and then centrifuge for ~1.5 min at 
10,000 x g, or until all the Nuclease-free Water is through the filter. 
k. Elute with a second 9 μL of preheated Nuclease-free Water. The double-
stranded cDNA will now be in the eluate (~14 μL). 
 
7.3.1.4. In Vitro Transcription to Synthesize Amino Allyl-Modified 
aRNA 
 
This is the amplification step and with aaUTP generates multiple copies of 
amino allyl-modified aRNA from the double-stranded cDNA templates. 
a. At room temp, assemble the IVT Master Mix at room temp in the order 
shown (for a single 40 μL reaction): 
  3 μL aaUTP (50 mM) 
12 μL ATP, CTP, GTP Mix (25 mM) 
3 μL UTP Solution (50 mM) 
4 μL T7 10X Reaction Buffer 
 4 μL T7 Enzyme Mix 
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b. Mix well by gently vortexing. Centrifuge briefly (~5 sec) to collect the 
IVT Master Mix at the bottom of the tube and place on ice. 
c. Transfer 26 μL of IVT Master Mix to each sample. Mix thoroughly by 
pipetting up and down 2–3 times, then flicking the tube 3–4 times, and 
centrifuge briefly to collect the reaction in the bottom of the tube. 
d. Once assembled, incubate the tubes for 14 hr at 37°C in the water bath. 
e. Stop the reaction by adding 60 μL Nuclease-free Water to each aRNA 
sample to bring the final volume to 100 μL. Mix thoroughly by gentle 
vortexing. 
Proceed to the aRNA purification. 
 
7.3.1.5. aRNA Purification 
 
This purification removes unincorporated aaUTP and Tris from IVT 
reactions that would otherwise compete with the aRNA for dye coupling; 
it also removes enzymes, salts, and other unincorporated nucleotides to 
improve the stability of the aRNA. 
Preheat Nuclease-free Water to 50–60°C 
a. Check to make sure that each IVT reaction was brought to 100 μL with 
Nuclease-free Water. 
b. Add 350 μL of aRNA Binding Buffer to each aRNA sample. Proceed to 
the next step immediately. 
c. Add 250 μL of ACS grade 100% ethanol to each aRNA sample, and mix 
by pipetting the mixture up and down 3 times. Proceed immediately to 
the next step as soon as you have mixed the ethanol into each sample. Any 
delay in proceeding could result in loss of 
aRNA because once the ethanol is added, the aRNA will be in a 
semiprecipitated state. 
d. Pipet each sample mixture onto the center of the filter in the aRNA 
Filter Cartridge. 
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e. Centrifuge for ~1 min at 10,000 X g. Continue until the mixture has 
passed through the filter. 
f. Discard the flow-through and replace the aRNA Filter Cartridge back 
into the aRNA Collection Tube. 
g. Apply 650 μL Wash Buffer to each aRNA Filter Cartridge. 
h. Centrifuge for ~1 min at 10,000 X g, or until all the Wash Buffer is 
through the filter. 
i. Discard the flow-through and spin the aRNA Filter Cartridge for an 
additional ~1 min to remove trace amounts of Wash Buffer. 
j. Transfer Filter Cartridge(s) to a fresh aRNA Collection Tube. 
k. To the center of the filter, add 70 μL Nuclease-free Water (preheated to 
50–60°C). 
l. Leave at room temp for 2 min and then centrifuge for ~1.5 min at 10,000 
X g, or until the Nuclease-free Water is through the filter. 
m. Repeat the steps j-k. 
n. The aRNA will now be in the aRNA Collection Tube in 140 μL of 
Nuclease-free Water. 
Store purified aRNA at –80°C. 
 
The concentration of the aRNA was been determined by measuring its 
absorbance at 260 nm using NanoDrop spectrophotometer.  
 
7.3.2. RNA LABELING 
 
7.3.2.1. aRNA:Dye Coupling Reaction 
 
The Dye takes place between the amino allyl-modified UTP residues on 
the aRNA and amine reactive Cy3 or Cy5 dyes. 
The steps are indicated following. 
a. Add 11 μL of DMSO to one tube of Cy3 or Cy5 reactive dye, and vortex 
to mix thoroughly. 
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b. Keep the resuspended dye in the dark at room temperature for up to 1 
hr until you are ready to use it. 
c. Vacuum dry on medium 5 μg of amino allyl-modified aRNA until no 
liquid remains. 
d. To the dried amino allyl aRNA (5 μg), add 9 μL Coupling Buffer and 
resuspend thoroughly by vortexing gently. 
e. Add 11 μL of prepared dye (from step a) to the aRNA:Coupling Buffer 
mixture. Mix well by vortexing gently. 
f. 60 min incubation at room temp allows the dye coupling reaction to 
occur.  
g. To quench the reaction, add 4.5 μL 4M Hydroxylamine and mix well by 
vortexing gently. 
h. Incubate the reaction in the dark at room temp for 15 min. (During this 
incubation, the large molar excess of hydroxylamine will quench the 
amine-reactive groups on the unreacted dye molecules.) 
i. Add 5.5 μL Nuclease-free Water to each sample to bring the volume to 
30 μL. 
 
7.3.2.2. Dye Labeled aRNA Purification 
 
This purification removes excess dye from the labeled aRNA and 
exchanges the 
buffer with Nuclease-free Water. 
Before beginning the labeled aRNA purification, preheat the bottle of 
Nuclease-free Water to 50–60°C for at least 10 min. 
a. Add 105 μL of aRNA Binding Buffer to each aRNA sample. Proceed to 
the next step immediately. 
b. Add 75 μL of ACS grade 100% ethanol to each labeled aRNA sample, 
and mix by pipetting the mixture up and down 3 times. Proceed 
immediately to the next step as soon as you have mixed the ethanol into 
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each sample. Any delay in proceeding could result in loss of aRNA 
because once the ethanol is added, the aRNA will be in a semiprecipitated 
state. 
c. Pipet each sample mixture onto the center of the filter in the Labeled 
aRNA Filter Cartridge. 
d. Centrifuge for ~1 min at 10,000 X g. Continue until the mixture has 
passed through the filter. 
e. Discard the flow-through and replace the Labeled aRNA Filter 
Cartridge back into the Labeled aRNA Collection Tube. 
f. Apply 500 μL Wash Buffer to each Labeled aRNA Filter Cartridge. 
g. Centrifuge for ~1 min at 10,000 X g, or until all the Wash Buffer passes 
through the filter. 
h. Discard the flow-through and centrifuge for an additional ~1 min to 
remove trace amounts of Wash Buffer. 
i. Transfer the Labeled aRNA Filter Cartridge to a Labeled aRNA Elution 
Tube. 
j. To the center of the filter, add 20 μL Nuclease-free Water that is 
preheated to 50–60°C. 
k. Leave at room temp for 2 min and then centrifuge for ~1.5 min at 10,000 
X g, or until the Nuclease-free Water is through the filter. 
l. Repeat steps j-k three times with 20 μL each of preheated Nuclease-free 
Water. 
m. The aRNA will now be in the Labeled aRNA Elution Tube in ~60 μL of 
Nuclease-free Water. 
n. Determine the aRNA concentration using NanoDrop. Measure the 
absorbance of each sample at 260 nm (A260) and also at the maximum 
absorbance wavelength for the dye used in the coupling reaction.   
The absorbance for Cy3 is at 550 nm and for Cy5 at 650 nm. 
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7.3.3. HYBRIDIZATION ON MICROARRAY PLATFORMS 
 
7.3.3.1. Pre-hybridization 
 
A pre-hybridization buffer is composed by: SSC 20X with final 
concentration of 5X, SDS 10% with final concentration of 0,1%, ssDNA 
with final concentration 100 ng/µl, Denhardt’s solution 50X with final 
concentration 5X and milliQ water to volume.  
About 80 µl of pre-hybridization buffer, preheat at 48°C, are pipetted on 
the glass. A cover glass is applied above and then the glass is positioned in 
a hybridization chamber (HybChamber of GeneMachines) with about 100 
µl of SSC 3X to avoid the evaporation of the buffer, then the formation of 
crystals.  
Incubate the prepared chamber in a water bath at 42°C for at least 4 hours.  
After the pre-hybridization, the glass had to be washed and then dried by 
centrifugation at room temperature at 1000 rpm for 1 minute.  
In Figure 11 is shown the used pre-hybridization chamber.   
 
 
Figure 11. Designed specifically for post-process microarraying, the  
HybChambers are easier to use than any other hybridization chambers  
on the market. 
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7.3.3.2. Hybridization  
 
Once pre-hybridizated, the glass is ready for the hybridization. 
The two labelled aRNA are put together and then washed and 
precipitated: 
- Add the 4/5 of the total volume in ammonium acetate  
- Add to the obtained volume 2,5 times of EtOH 100% 
- Put at -20°C for at least 2 hr 
- Centrifugate at 13000 g for 20 min at 4°C 
- Throw away the supernatant and keep the pellet 
- Wash with 500 µl EtOH 75% 
-  Centrifugate at 13000 g for 12 min at 4°C 
- Throw away the supernatant and keep the pellet 
- Second wash with 300 µl EtOH 75% 
- Centrifugate at 13000 g for 16 min at 4°C 
- Throw away the supernatant 
- Keep in the dark  
Preheat the hybridization buffer at 48°C 
The hybridization buffer is composed by SSC 20X with final concentration 
of 5X, SDS 10% with final concentration of 0,1%, formamide final 
concentration 50% and milliQ water to volume. 
Dissolve the pellet in 10 µl of DEPC-treated Water and add 110 µl of 
hybridization buffer.  
Denature the sample at 65°C for 1 minute.  
The 120 µl sample is pipetted on the glass. A cover glass is applied above 
and then the glass is positioned in the hybridization chamber 
(HybChamber of GeneMachines).  
Incubate the prepared chamber in a water bath at 42°C for 40 hours. 
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7.3.3.3. Post-hybridization  
 
The glass had to be washed with: 
1X SSC 0,1% SDS for 5 minutes 
0,2X SSC 0,1% SDS for 5 minutes 
0,2X SSC for 5 minutes 
0,1X SSC for 2 minutes 
Then we could proceed with the scan of the microarray. 
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8. ABBREVIATIONS 
 
 
TAA = thoracic aortic aneurysm 
SMC = smooth muscle cell 
PTGS = post-transcriptional gene regulation 
BAV = bicuspid aortic valve 
TAV = tricuspid aortic valve 
ECM = extracellular matrix 
ASMC = arterial smooth muscle cell 
SCN = suprachiasmatic nucleus 
AscAA = ascending aortic aneurysm 
NRQ = normalized relative quantities
 55
9. REFERENCES 
 
 
1. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, 
pathogenesis, and etiology of thoracic aortic aneurysms and 
dissections. Cardiol Clin. 1999 Nov;17(4):615-35. 
 
2. Spina M, Garbisa S, Hinnie J, Hunter JC, Serafini-Fracassini A. Age-
related changes in composition and mechanical properties of the 
tunica media of the upper thoracic human aorta. Arteriosclerosis. 
1983 Jan-Feb;3(1):64-76. 
 
3. Ince H, Nienaber CA. Etiology, pathogenesis and management of 
thoracic aortic aneurysm. Nat Clin Pract Cardiovasc Med. 2007 
Aug;4(8):418-27. 
 
4. Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, 
Cherry KJ, Joyce JW, Lie JT. Thoracic aortic aneurysms: a 
population-based study. Surgery. 1982 Dec;92(6):1103-8. 
 
5. Gillum RF. Epidemiology of aortic aneurysm in the United States. J 
Clin Epidemiol. 1995 Nov;48(11):1289-98. 
 
6. Milewicz DM, Chen H, Park ES, Petty EM, Zaghi H, Shashidhar G, 
Willing M, Patel V. Reduced penetrance and variable expressivity 
of familial thoracic aortic aneurysms/dissections. Am J Cardiol. 
1998 Aug 15;82(4):474-9. 
 
7. Feindel CM, David TE. Aortic valve sparing operations: basic 
concepts. Int J Cardiol. 2004 Dec;97 Suppl 1:61-6. 
 
8. Ikonomidis JS, Jones JA, Barbour JR, Stroud RE, Clark LL, Kaplan 
BS, Zeeshan A, Bavaria JE, Gorman JH 3rd, Spinale FG, Gorman 
RC. Expression of matrix metalloproteinases and endogenous 
inhibitors within ascending aortic aneurysms of patients with 
bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 
Apr;133(4):1028-36. Epub 2007 Feb 26. 
 
9. Matt P, Carrel T, White M, Lefkovits I, Van Eyk J. Proteomics in 
cardiovascular surgery. J Thorac Cardiovasc Surg. 2007 
Jan;133(1):210-4. 
 
 56
10. Zerkowski HR, Grussenmeyer T, Matt P, Grapow M, Engelhardt S, 
Lefkovits I. Proteomics strategies in cardiovascular research. J 
Proteome Res. 2004 Mar-Apr;3(2):200-8. 
 
11. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian 
microRNAs: a small world for fine-tuning gene expression. Mamm 
Genome. 2006 Mar;17(3):189-202. Epub 2006 Mar 3. 
 
12. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle 
J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows 
that some microRNAs downregulate large numbers of target 
mRNAs. Nature. 2005 Feb 17;433(7027):769-73. Epub 2005 Jan 30. 
 
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell. 2004 Jan 23;116(2):281-97. 
 
14. Bonderman D, Gharehbaghi-Schnell E, Wollenek G, Maurer G, 
Baumgartner H, Lang IM. Mechanisms underlying aortic dilatation 
in congenital aortic valve malformation. Circulation 99: 2138, 1999. 
 
15. Fedak P. W, de Sa MP, Verma S, Nili N, Kazemian P, Butany J, 
Strauss BH, Weisel RD, David TE. Vascular matrix remodeling in 
patients with bicuspid aortic valve malformations: Implications for 
aortic dilatation. J. Thorac. Cardiovasc. Surg. 126: 797, 2003. 
 
16. Schmid FX, Bielenberg K, Schneider A, Haussler A, Keyser A, 
Birnbaum D. Ascending aortic aneurysm associated with bicuspid 
and tricuspid aortic valve: Involvement and clinical relevance of 
smooth muscle cell apoptosis and expression of cell death-initiating 
proteins. Eur. J. Cardiothorac. Surg. 23: 537, 2003. 
 
17. Boyum J, Fellinger EK, Schmoker JD, Trombley L, McPartland K, 
Ittleman FP, Howard AB. Matrix metalloproteinase activity in 
thoracic aortic aneurysms associated with bicuspid and tricuspid 
aortic valves. J. Thorac. Cardiovasc. Surg. 127: 686, 2004. 
 
18. Collins MJ, Dev V, Strauss BH, Fedak PW, Butany J. Variation in 
the histopathological features of patients with ascending aortic 
aneurysms: a study of 111 surgically excised cases. J Clin Pathol. 
2008 Apr;61(4):519-23. Epub 2007 Oct 15. 
 
19. LeMaire SA, Wang X, Wilks JA, Carter SA, Wen S, Won T, 
Leonardelli D, Anand G, Conklin LD, Wang XL, Thompson RW, 
Coselli JS. Matrix metalloproteinases in ascending aortic 
 57
aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res. 2005 
Jan;123(1):40-8. 
 
20. Hall G, Hasday JD, Rogers TB Regulating the regulator: NF-kB 
signaling in the heart. J Mol Cell Cardiol 41 (2006) 580-591. 
 
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal 
Biochem. 1987 Apr;162(1):156-9. 
 
22. Cagnin S, Biscuola M, Patuzzo C, Trabetti E, Pasquali A, Laveder P, 
Faggian G, Iafrancesco M, Mazzucco A, Pignatti PF, Lanfranchi G. 
Reconstruction and functional analysis of altered molecular 
pathways in human atherosclerotic arteries. BMC Genomics. 2009 
Jan 9;10(1):13. 
 
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De 
Paepe A, Speleman F. Accurate normalization of real-time 
quantitative RT-PCR data by geometric averaging of multiple 
internal control genes. Genome Biol. 2002 Jun 
18;3(7):RESEARCH0034. Epub 2002 Jun 18. 
 
24. Isselbacher EM. Thoracic and abdominal aortic aneurysms. 
Circulation. 2005 Feb 15;111(6):816-28. 
 
25. Koullias GJ, Ravichandran P, Korkolis DP, Rimm DL, Elefteriades 
JA. Increased tissue microarray matrix metalloproteinase 
expression favors proteolysis in thoracic aortic aneurysms and 
dissections. Ann Thorac Surg. 2004 Dec;78(6):2106-10; discussion 
2110-1. 
 
26. Absi TS, Sundt TM 3rd, Tung WS, Moon M, Lee JK, Damiano RR Jr, 
Thompson RW. Altered patterns of gene expression distinguishing 
ascending aortic aneurysms from abdominal aortic aneurysms: 
complementary DNA expression profiling in the molecular 
characterization of aortic disease. J Thorac Cardiovasc Surg. 2003 
Aug;126(2):344-57; discission 357. 
 
27. Taketani T, Imai Y, Morota T, Maemura K, Morita H, Hayashi D, 
Yamazaki T, Nagai R, Takamoto S. Altered patterns of gene 
expression specific to thoracic aortic aneurysms: microarray 
 58
analysis of surgically resected specimens. Int Heart J. 2005 
Mar;46(2):265-77. 
 
28. Klima T, Spjut HJ, Coelho A, Gray AG, Wukasch DC, Reul GJ Jr, 
Cooley DA. The morphology of ascending aortic aneurysms. Hum 
Pathol. 1983 Sep;14(9):810-7. 
 
29. Savunen T, Aho HJ. Annulo-aortic ectasia. Light and electron 
microscopic changes in aortic media. Virchows Arch A Pathol Anat 
Histopathol. 1985;407(3):279-88. 
 
30. Keene DR, San Antonio JD, Mayne R, McQuillan DJ, Sarris G, 
Santoro SA, Iozzo RV. Decorin binds near the C terminus of type I 
collagen. J Biol Chem. 2000 Jul 21;275(29):21801-4. 
 
31. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, 
Iozzo RV. Targeted disruption of decorin leads to abnormal 
collagen fibril morphology and skin fragility. J Cell Biol. 1997 Feb 
10;136(3):729-43. 
 
32. Pentikäinen MO, Oörni K, Lassila R, Kovanen PT. The proteoglycan 
decorin links low density lipoproteins with collagen type I. J Biol 
Chem. 1997 Mar 21;272(12):7633-8. 
 
33. Ralph MR, Foster RG, Davis FC, Menaker M. Transplanted 
suprachiasmatic nucleus determines circadian period. Science. 1990 
Feb 23;247(4945):975-8. 
 
34. Martino TA, Tata N, Belsham DD, Chalmers J, Straume M, Lee P, 
Pribiag H, Khaper N, Liu PP, Dawood F, Backx PH, Ralph MR, Sole 
MJ. Disturbed diurnal rhythm alters gene expression and 
exacerbates cardiovascular disease with rescue by 
resynchronization. Hypertension. 2007 May;49(5):1104-13. Epub 
2007 Mar 5. 
 
35. Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks 
in the vasculature. Arterioscler Thromb Vasc Biol. 2007 
Aug;27(8):1694-705. Epub 2007 May 31. 
 
36. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker 
C, Poole WK, Passamani E, Roberts R, Robertson T, et al. Circadian 
variation in the frequency of onset of acute myocardial infarction. N 
Engl J Med. 1985 Nov 21;313(21):1315-22. 
 59
 
37. Muller JE, Ludmer PL, Willich SN, Tofler GH, Aylmer G, Klangos I, 
Stone PH. Circadian variation in the frequency of sudden cardiac 
death. Circulation. 1987 Jan;75(1):131-8. 
 
38. Portaluppi F, Manfredini R, Fersini C. From a static to a dynamic 
concept of risk: the circadian epidemiology of cardiovascular 
events. Chronobiol Int. 1999 Jan;16(1):33-49. 
 
39. Manfredini R, Gallerani M, Portaluppi F, Fersini C. Relationships of 
the circadian rhythms of thrombotic, ischemic, hemorrhagic, and 
arrhythmic events to blood pressure rhythms. Ann N Y Acad Sci. 
1996 Aug 15;783:141-58. 
 
40. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of 
blood-pressure. Lancet. 1978 Apr 15;1(8068):795-7. 
 
41. Manfredini R, Boari B, Gallerani M, Salmi R, Bossone E, Distante A, 
Eagle KA, Mehta RH. Chronobiology of rupture and dissection of 
aortic aneurysms. J Vasc Surg. 2004 Aug;40(2):382-8. 
 
42. Anderson L, Seilhamer J. A comparison of selected mRNA and 
protein abundances in human liver. Electrophoresis. 1997 Mar-
Apr;18(3-4):533-7. 
 
43. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between 
protein and mRNA abundance in yeast. Mol Cell Biol. 1999 
Mar;19(3):1720-30. 
 
44. Hegde PS, White IR, Debouck C. Interplay of transcriptomics and 
proteomics. Curr Opin Biotechnol. 2003 Dec;14(6):647-51. 
 
45. Iso T, Hamamori Y, Kedes L. Notch signaling in vascular 
development. Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):543-
53. Epub 2003 Feb 13. 
 
46. Karsan A. The role of notch in modeling and maintaining the 
vasculature. Can J Physiol Pharmacol. 2005 Jan;83(1):14-23. 
 
47. Lindner V, Booth C, Prudovsky I, Small D, Maciag T, Liaw L. 
Members of the Jagged/Notch gene families are expressed in 
injured arteries and regulate cell phenotype via alterations in cell 
matrix and cell-cell interaction. Am J Pathol. 2001 Sep;159(3):875-83. 
 
 60
48. Yang G, Wu L, Wang R. Pro-apoptotic effect of endogenous H2S on 
human aorta smooth muscle cells. FASEB J. 2006 Mar;20(3):553-5. 
Epub 2006 Jan 17. 
 
49. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as 
a novel endogenous gaseous K(ATP) channel opener. EMBO J. 2001 
Nov 1;20(21):6008-16. 
 
50. Zhao W, Wang R. H(2)S-induced vasorelaxation and underlying 
cellular and molecular mechanisms. Am J Physiol Heart Circ 
Physiol. 2002 Aug;283(2):H474-80. 
 
51. Wang R. Two's company, three's a crowd: can H2S be the third 
endogenous gaseous transmitter? FASEB J. 2002 Nov;16(13):1792-8. 
 
52. Astrof S, Hynes RO. Fibronectins in vascular morphogenesis. 
Angiogenesis. 2009 Feb 14. [Epub ahead of print] 
 
53. Majumdar R, Miller DV, Ballman KV, Unnikrishnan G, McKellar 
SH, Sarkar G, Sreekumar R, Bolander ME, Sundt TM 3rd. Elevated 
expressions of osteopontin and tenascin C in ascending aortic 
aneurysms are associated with trileaflet aortic valves as compared 
with bicuspid aortic valves. Cardiovasc Pathol. 2007 May-
Jun;16(3):144-50. Epub 2007 Feb 21. 
 
54. Robicsek F. Bicuspid versus tricuspid aortic valves. J Heart Valve 
Dis. 2003 Jan;12(1):52-3. 
 
55. Parai JL, Masters RG, Walley VM, Stinson WA, Veinot JP. Aortic 
medial changes associated with bicuspid aortic valve: myth or 
reality? Can J Cardiol. 1999 Nov;15(11):1233-8. 
 
56. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang 
ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal 
M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano 
P, Peterson KL, Croce CM, Peschle C, Condorelli G. MicroRNA-133 
controls cardiac hypertrophy. Nat Med. 2007 May;13(5):613-8. Epub 
2007 Apr 29. 
 
57. Isenberg JS, Roberts DD, Frazier WA. CD47: a new target in 
cardiovascular therapy. Arterioscler Thromb Vasc Biol. 2008 
Apr;28(4):615-21. Epub 2008 Jan 10. 
 
 61
58. Scalbert E, Bril A. Implication of microRNAs in the cardiovascular 
system. Curr Opin Pharmacol. 2008 Apr;8(2):181-8. Epub 2008 Feb 
19. 
